Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.405
-0.005 (-0.11%)
Nov 28, 2025, 4:00 PM EST - Market closed
Arbutus Biopharma Revenue
Arbutus Biopharma had revenue of $529.00K in the quarter ending September 30, 2025, a decrease of -60.49%. This brings the company's revenue in the last twelve months to $14.61M, up 116.64% year-over-year. In the year 2024, Arbutus Biopharma had annual revenue of $6.17M, down -65.98%.
Revenue (ttm)
$14.61M
Revenue Growth
+116.64%
P/S Ratio
57.65
Revenue / Employee
$331,955
Employees
44
Market Cap
847.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.17M | -11.97M | -65.98% |
| Dec 31, 2023 | 18.14M | -20.88M | -53.51% |
| Dec 31, 2022 | 39.02M | 28.03M | 255.11% |
| Dec 31, 2021 | 10.99M | 4.07M | 58.92% |
| Dec 31, 2020 | 6.91M | 903.00K | 15.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABUS News
- 15 days ago - Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 - GlobeNewsWire
- 4 months ago - Arbutus (ABUS) Q2 Revenue Surges 529% - The Motley Fool
- 4 months ago - Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus - GlobeNewsWire
- 7 months ago - Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 - GlobeNewsWire
- 7 months ago - Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - GlobeNewsWire